INTRODUCTION
Emerging evidence has demonstrated that monoclonal antibodies (mAbs) either alone or in combination are an effective modality for cancer treatment (Adams and Weiner, 2005) . Although therapies combining a mAb with chemotherapeutic agents are effective in several human cancers, antibodies alone are not curative. Antibodies effective against cancer are believed to function by several mechanisms including antibody-dependent cellular cytotoxicity (ADCC), stimulation of complementdependent cytotoxicity (CDC), inhibition of signal transduction, or direct induction of apoptosis (Cheson and Leonard, 2008) .
Non-Hodgkin lymphoma (NHL) is the fifth most common cancer in the United States consisting of indolent and aggressive subtypes with a 5 year overall survival ranging from 25%-75% (The International Non-Hodgkin's Lymphoma Prognostic Factors Project, 1993) . The anti-CD20 antibody, rituximab (Rituxan) , is a standard therapy for many CD20-positive B cell lymphomas and significantly improves long-term survival in combination with conventional chemotherapy (Cheson and Leonard, 2008) . As a single agent or in combination with chemotherapy, rituximab is not curative in the majority of B cell NHL patients and rituximab resistance has been observed (reviewed in Cheson and Leonard, 2008) . Multiple lines of evidence indicate that rituximab acts at least in part by engaging Fc receptors (FcRs) on immune effector cells, such as NK cells and macrophages, and stimulating effector functions such as ADCC (Glennie et al., 2007; Nimmerjahn and Ravetch, 2007) . Although resistance has been reported to occur through several mechanisms (Cartron et al., 2004) , there has been limited development of agents that can overcome this resistance.
Immune effector cells, including NK cells and phagocytes, are critical to the efficacy of many anticancer antibodies. Phagocytic cells, including macrophages and dendritic cells, express signal regulatory protein alpha (SIRPa), which binds CD47, a widely expressed transmembrane protein (Brown and Frazier, 2001 ). CD47-mediated activation of SIRPa initiates a signal transduction cascade resulting in inhibition of phagocytosis (reviewed in Jaiswal et al., 2010) . In identifying a role for CD47 in cancer pathogenesis, we previously demonstrated that forced expression of mouse CD47 on a human leukemia cell line facilitated tumor engraftment in immunodeficient mice through the evasion of phagocytosis . We further demonstrated that this mechanism could be targeted therapeutically in human acute myeloid leukemia (AML) with a blocking anti-CD47 antibody that enabled phagocytosis and eliminated AML stem cells ). Based on this antibody mechanism, we hypothesized that the combination of a blocking anti-CD47 antibody with a second FcR-activating antibody would both prevent an inhibitory signal and deliver a positive stimulus, resulting in the synergistic phagocytosis and elimination of target cells. Here, we tested this antibody synergy hypothesis by investigating the combination of a blocking anti-CD47 mAb with rituximab against human NHL.
RESULTS

CD47 Expression Is Increased on NHL Cells Compared to Normal B Cells
We examined CD47 protein expression on primary human NHL samples and normal B cells by flow cytometry. Compared to both normal peripheral blood and germinal center B cells, CD47 was more highly expressed on a large subset of primary patient samples from multiple B cell NHL subtypes ( Figure 1A and Figure S1A available online), including diffuse large B cell lymphoma (DLBCL), B cell chronic lymphocytic leukemia (B-CLL), mantle cell lymphoma (MCL), follicular lymphoma (FL), marginal zone lymphoma (MZL), and pre-B acute lymphoblastic leukemia (pre-B ALL). Across NHL subtypes, we found differing levels of CD47 expression that also varied within each NHL subtype ( Figure 1B ).
Increased CD47 Expression Correlates with a Worse Clinical Prognosis and Adverse Molecular Features in Multiple NHL Subtypes
Having previously shown a correlation between CD47 mRNA and protein expression , we assessed CD47 mRNA expression across NHL subtypes for associations with morphologic and molecular subgroups using gene expression data from previously described patient cohorts (Table S1 ) and investigated the prognostic implications of increased CD47 expression in disease outcome. Higher CD47 expression was associated with adverse prognosis in DLBCL, B-CLL, and MCL ( Figures 1C-1E ). In patients with DLBCL, whether treated with or without rituximab-based combination chemotherapy (Figure 1C and Figure S1B ), higher CD47 expression was significantly associated with risk of death. This increased risk was largely due to disease progression ( Figure S1C ), a finding validated in an independent cohort of patients using quantitative RT-PCR on fixed archival specimens ( Figure S1D ).
We next investigated whether increased CD47 expression was associated with known adverse molecular features in NHL. In DLBCL, prior studies have identified two distinct subgroups based on the presumed cell of origin of tumors: normal germinal center B cells (GCB-like), which are associated with a favorable clinical outcome, or activated blood memory B cells (ABC-like), which are associated with a poor clinical outcome (Alizadeh et al., 2000; Rosenwald et al., 2002) . CD47 expression was significantly higher in ABC-like DLBCL ( Figure 1F and Figure S1E ). CD47 expression was not found to have independent prognostic value within GCB and ABC subtypes, suggesting a strong association with the cell-of-origin classification of DLBCL. Higher CD47 expression was also associated with unmutated immunoglobulin heavy chain variable regions (IgVH) in CLL ( Figure 1G and Figure S1E ) and significantly correlated with the proliferative index in MCL ( Figure 1H ), both known adverse prognostic factors (Katzenberger et al., 2006; Oscier et al., 2002; Rosenwald et al., 2003) . In multivariate analyses, CD47 expression remained prognostic of disease progression independent from the international prognostic index in DLBCL (The International Non-Hodgkin's Lymphoma Prognostic Factors Project, 1993) and two major prognostic factors in CLL: IgVH mutation status and ZAP-70 status ( Figure S1G ). Within the small MCL cohort, a multivariate model did not find independent prognostic value for CD47 when considering the proliferation index (data not shown).
Blocking Anti-CD47 Antibodies Enable Phagocytosis of NHL Cells by Macrophages and Synergize with Rituximab In Vitro
We first tested the ability of anti-human CD47 antibodies to enable phagocytosis of human NHL cell lines, primary NHL cells, and normal peripheral blood (NPB) cells by human macrophages in vitro. Incubation of NHL cells in the presence of IgG1 isotype control or anti-CD45 IgG1 antibody did not result in significant phagocytosis; however, two different blocking anti-CD47 antibodies (B6H12.2 and BRIC126) enabled phagocytosis of NHL cells but not NPB cells (Figures 2A and 2B) .
Next, we repeated the in vitro phagocytosis assays with mouse macrophages. Incubation of NHL cells in the presence of IgG1 isotype control or anti-CD45 IgG1 antibody did not result in significant phagocytosis; however, phagocytosis of NHL cells was observed with blocking antibodies to CD47 (B6H12.2 and BRIC126), whereas no phagocytosis was observed with a nonblocking antibody (2D3) ( Figure 2B ). Disruption of the CD47-SIRPa interaction with an anti-mouse SIRPa antibody also resulted in significant phagocytosis ( Figure 2B ).
Given variable expression of CD47 on primary NHL, we investigated by two independent methods whether CD47 expression levels correlated with the degree of anti-CD47 antibody-mediated phagocytosis. First, lentiviral shRNA vectors were used to knock down expression of CD47 in Raji cells. Several clones were generated with a range of CD47 knockdown (Figures S2A and S2B) . Those clones with a greater than 50% reduction in CD47 expression (shCD47-1 and shCD47-2) demonstrated a significant reduction in anti-CD47 antibody-mediated phagocytosis ( Figure S3C ). In the second approach, a statistical analysis demonstrated a positive correlation between CD47 expression and degree of anti-CD47 antibody-mediated phagocytosis with both mouse and human macrophage effector cells ( Figure S2D ). (C-E) Prognostic influence of CD47 mRNA expression is shown on overall (C and E) and event-free (D) survival of patients with DLBCL, B-CLL, and MCL. For DLBCL and CLL, stratification into low and high CD47 expression groups was based on an optimal threshold determined by microarray analysis; this cutpoint was internally validated for both DLBCL and CLL and also externally validated in an independent DLBCL cohort. For MCL, stratification relative to the median was employed as an optimal cutpoint could not be defined. Significance measures are based on log-likelihood estimates of the p value, when treating CD47 expression as a continuous variable, with corresponding dichotomous indices also provided in Table S1 . (F-H) CD47 mRNA expression is shown in relation to cell-of-origin classification for DLBCL (F), immunoglobulin heavy chain mutation status (IgVH) for CLL (G), and proliferation index for MCL (H). Error bars represent upper and lower quartiles (F and G). Analyses for (C)-(H) employed publicly available datasets for NHL patients (Table S1 ). NGC = normal germinal center, ABC = activated B cell-like, GCB = germinal center B cell-like. See also Figure S1 and Table S1. It has been reported that immobilized or crosslinked antibodies against CD47 induce apoptosis of primary human B-CLL cells, as well as several malignant lymphoid cell lines (Kikuchi et al., 2004 (Kikuchi et al., , 2005 Mateo et al., 1999; Uno et al., 2007) . Therefore, anti-CD47 antibodies might be predicted to directly induce apoptosis of NHL cells that are then recognized by macrophages and phagocytosed. Contrary to this prediction, when NHL cells were incubated with anti-CD47 antibody in the absence of macrophages, no induction of apoptosis was observed when cells were incubated in suspension for either 2 hr ( Figure 2B , right) or 8 hr ( Figures S2E and S2F) . Incubation of NHL cells with immobilized anti-CD47 antibody resulted in increased apoptosis compared to controls (Figures S2G and S2H) , consistent with prior reports (Mateo et al., 1999) . Given that phagocytosis of NHL cells occurs in the presence of soluble anti-CD47 mAbs, it is unlikely that these mAbs induce apoptosis of NHL cells that are then secondarily phagocytosed.
Next, we tested the ability of a blocking anti-CD47 mAb to synergize with rituximab in the phagocytosis of NHL cells. We examined CD20 expression on NHL cells and found no difference between normal B cells and NHL cells (Figures S2I and S2J) . Incubation of NHL cells with rituximab in the presence of mouse or human macrophages resulted in significant phagocytosis (Figures 2D and S2E) . We then tested the synergy hypothesis by isobologram analysis (Chou, 2008; Tallarida, 2006) . Using Raji, SUDHL4, and NHL17 cells, which express varying levels of both CD47 and CD20 ( Figure S2K ), anti-CD47 antibody synergized with rituximab or anti-human CD20 (mouse IgG2a) antibody, as indicated by combination indices less than 1 (Figure 2C) . In a second approach, in vitro phagocytosis assays were conducted with primary NHL cells incubated with either anti-CD47 antibody or rituximab alone, or both in combination at half of the single agent dose. NHL cells exhibited a significant increase in phagocytosis when incubated with the combination compared to either antibody alone when using mouse (Figure 2D) or human ( Figure 2E ) macrophage effectors. No phagocytosis of NPB cells was observed with either antibody alone or in combination with human macrophages ( Figure 2E ).
Ex Vivo Coating of NHL Cells with an Anti-CD47 Antibody Inhibits Tumor Engraftment Next, the ability of blocking anti-CD47 antibody to eliminate NHL in vivo either alone or in combination with rituximab was explored by two separate treatment strategies. First, the effect of ex vivo anti-CD47 antibody coating on the engraftment of human NHL cells was tested. Luciferase-expressing Raji and SUDHL4 cell lines were precoated ex vivo with anti-CD47, IgG1 isotype control, or anti-CD45 antibody and transplanted intravenously into SCID mice. Coating with anti-CD47 antibody prevented engraftment of both cell lines ( Figures 3A-3F ). Coating of Raji cells with rituximab also inhibited engraftment when transplanted into SCID mice ( Figure S3 ). In addition to these cell lines, we identified a primary NHL patient specimen that engrafted in NSG mice in the bone marrow upon intravenous transplantation (Figures S5A and S5B) . As with the cell lines, ex vivo coating of these primary cells with anti-CD47 antibody, but not controls ( Figure 3G ), resulted in complete inhibition of bone marrow engraftment ( Figure 3H ).
Combination Therapy with Anti-CD47 Antibody and Rituximab Eliminates Lymphoma in Both Disseminated and Localized Human NHL Xenotransplant Models In the second treatment strategy, mice were first engrafted with NHL and then administered single or combination antibody therapy. To best model NHL, we established disseminated and localized xenotransplantation models in NSG mice that are deficient in T, B, and NK cells (Shultz et al., 2005) but retain phagocyte effector cells. In the disseminated model, luciferaseexpressing Raji cells were transplanted intravenously into adult NSG mice. Two weeks later, these mice were administered daily injections of either control mouse IgG, anti-CD47 antibody, rituximab, or anti-CD47 antibody and rituximab. Anti-CD47 antibody treatment decreased the lymphoma burden in these mice (Figures 4A and 4B) and significantly prolonged survival compared to control IgG, although all mice eventually died ( Figure 4C and Table S2 ). Similar results were seen with rituximab and were not statistically different compared to anti-CD47 antibody (Figures 4A-4C and Table S2 ). In contrast, combination therapy with anti-CD47 antibody and rituximab eliminated lymphoma in 60% of mice as indicated by long-term survival ( Figure 4C ) and the absence of luciferase-positive lymphoma (data not shown) more than 4 months after the end of treatment. In humans, rituximab efficacy is thought to be primarily mediated by both macrophages and NK cells (Nimmerjahn and Ravetch, 2007; Taylor and Lindorfer, 2008) . Given that NSG mice lack NK cells, we conducted a similar experiment in NK cell-containing SCID mice and observed similar therapeutic responses as in NSG mice ( Figures  S4A and S4B ).
In the localized NHL model, luciferase-expressing Raji cells were transplanted subcutaneously in the right flank of NSG mice. Once tumors were palpable (approximately 2 weeks), mice were treated with antibody therapy. Mice treated with anti-CD47 antibody or rituximab demonstrated a decreased rate of lymphoma growth compared to control IgG-treated mice as measured by both luciferase signal and tumor volume ( Figures 4D-4F ) but, like controls, eventually had to be sacrificed due to enlarged tumor growth. In contrast, mice treated with the combination of anti-CD47 antibody and rituximab demonstrated complete elimination of lymphoma, with 86% of treated mice having no measurable mass or luciferase-positive lymphoma 4 weeks after the end of therapy ( Figures 4D-4F and Figures  S4C-S4E ). Moreover, all showed no evidence of tumor growth, (C) Synergistic phagocytosis by anti-CD47 antibody (B6H12.2) and anti-CD20 mAbs was examined by isobologram analysis and determination of combination indices (CI). CI obs indicates observed results, and the dashed line indicates the expected results if antibodies were additive. (D and E) Synergy between anti-CD47 antibody and rituximab in the phagocytosis of NHL and NPB cells was assessed by determining the phagocytic index when incubated with a combination of both antibodies compared to either antibody alone at twice the dose, with either mouse (D) or human (E) macrophages. NHL17*: cell line derived from primary sample NHL17. ***p < 0.001, ****p < 0.0001, *****p < 0.00001. Figure remained relapse free, and were alive at over 197 days after tumor engraftment. Out of six mice achieving a complete remission, five remained relapse free whereas one mouse died of nontumor-related causes ( Figure 4E ). For both disseminated and localized xenograft models, expression of CD47 and CD20 in transplanted Raji cells did not differ from Raji cells in culture ( Figure S4F ).
Combination Therapy with Anti-CD47 Antibody and Rituximab Eliminates Lymphoma in Primary Human NHL Xenotransplant Mouse Models NHL cell lines have been valuable for the evaluation of therapeutics, but they may not accurately recapitulate the heterogeneity of the primary disease. We report here two new mouse xenograft models for NHL in which intravenous transplantation of cells from a DLBCL patient (NHL7/SUNHL7) and a FL patient (NHL31/SUNHL31) give rise to robust lymphoma engraftment in the bone marrow and/or peripheral blood ( Figure S1A and Figure S5A ). Primary DLBCL cells were transplanted into mice, which 2 weeks later were treated with daily injections of antibodies for 14 days. Treatment with anti-CD47 antibody either alone or in combination with rituximab eliminated human lymphoma in the bone marrow, whereas treatment with rituximab resulted in a reduction of disease in 60% of mice (Figures 5A and 5B) . Mouse hematopoietic cells were unaffected by antibody therapy ( Figure S5E ). Treatment was then discontinued, and all mice were monitored for survival. Mice treated with either anti-CD47 antibody or rituximab alone had a significantly longer survival compared to mice treated with control IgG, but all eventually died secondary to disease due to widespread organ dissemination on autopsy ( Figure 5C , data not shown). Most significantly, 8 out of 9 mice (89%) administered combination antibody treatment were cured of lymphoma, as indicated by long-term disease-free survival more than 4 months after the end of treatment ( Figure 5C and Table S3 ) with no detectable lymphoma in the bone marrow (data not shown). In a second primary model, FL cells were transplanted intravenously in a similar manner. CD20 + CD10
+ lymphoma engraftment in the peripheral blood and bone marrow was detected after 8 weeks.
At this time, mice were treated with a single intraperitoneal injection of either control IgG, anti-CD47 antibody, rituximab, or the combination and then followed for disease progression. A single dose of anti-CD47 antibody alone or in combination with rituximab eliminated lymphoma both in the peripheral blood (Figure 5D ) and in bone marrow ( Figure 5E ). In contrast, a single dose of rituximab enabled a partial reduction in tumor burden that rebounded back to baseline levels in the peripheral blood with no tumor reduction observed in the bone marrow. The difference in anti-CD47 antibody clearance of lymphoma as a single dose in FL-engrafted mice ( Figures 5D and 5E ) compared to multiple dose therapy in mice engrafted with DLBCL (Figure 5B) or Raji (Figure 4 ) may be due to cell-intrinsic differences in antibody sensitivity between different NHL subtypes or due to different anti-CD47 antibody potencies in distinct tissue compartments (peripheral blood versus bone marrow (BM) versus soft tissue compartments).
To assess the ability of these two primary NHL xenotransplant models to model the disease, we compared histological sections of the primary NHL specimen and the transplanted tumor. Similar DLBCL and FL morphology was observed for NHL7 and NHL31, respectively ( Figure S5B ). We next determined whether the percentages of macrophages infiltrating the tumor differed between the primary patient and the xenografted tumor. For NHL31, the percentage of infiltrating human macrophages (CD68 + ) in the primary lymph node was similar to the percentage of infiltrating mouse macrophages (F4/80 + ) in bone marrow of transplanted mice ( Figure S5C ). Analyzing infiltrating macrophage frequency by flow cytometry, no difference was observed between the primary specimen and xenograft for either NHL7 or NHL31 ( Figure S5D ).
Synergy between Anti-CD47 Antibody and Rituximab Does Not Occur through NK Cells or Complement Rituximab can eliminate malignant cells via apoptosis, NK cellmediated ADCC, and CDC (reviewed in Smith, 2003) . However, it is not known whether anti-CD47 antibody also enables ADCC or CDC in addition to phagocytosis. Therefore, we investigated whether anti-CD47 antibody alone could induce antitumor effects by macrophage-independent mechanisms, and whether synergy with rituximab could occur through these modalities. First, to investigate possible synergy in direct apoptosis, NHL cells were incubated with either anti-CD47 antibody/rituximab alone or in combination without macrophages, and cell death was measured. No synergistic apoptosis was observed when NHL cells were incubated with soluble ( Figure 6A and Figure S6A ) or immobilized ( Figures S6B and S6C) antibodies. Furthermore, crosslinking of soluble anti-CD47 antibody alone or in combination with rituximab by macrophages did not induce increased apoptosis of nonphagocytosed NHL cells compared to IgG1 isotype control, whereas rituximab induced a slight increase in apoptosis ( Figure S6D ). No synergistic apoptosis was observed in this context ( Figure S6D ). The small increase in apoptosis upon antibody treatment was not FcR dependent given that results were similar with macrophages lacking the Fcg subunit (Takai et al., 1994 ) ( Figure S6D ). Second, we investigated whether NK cells could mediate tumor elimination by anti-CD47 antibody alone or in synergy with rituximab. A prior report observed increased NK cell cytotoxicity of cancer cell lines with an anti-CD47 antibody in vitro, though the mechanism of targeting was not elucidated (Kim et al., 2008) . We first determined whether human or mouse NK cells expressed SIRPa and found that both human NK cells, CD3 Figure S4 and Table S2 . (Table S3) (E) Lyphoma engraftment in the bone marrow was determined 14 days post-treatment. Each antibody treatment group consisted of three mice. For mice reported in (D) and (E), human lymphoma chimerism was between 5% and 25% in the peripheral blood and bone marrow. Error bars represent SD (D and E). See also Figure S5 and Table S3 . (C and D) Chromium release assays measuring ADCC were performed in triplicate with human (C) and mouse (D) at an effector:target ratio of 17.5:1, and percentspecific lysis is reported. Antibodies were incubated at 10 mg/ml except anti-CD47 full-length or F(ab 0 ) 2 antibody+rituximab (5 mg/ml).
(E) CDC assay with human complement was performed in duplicate. Compared to IgG1 isotype control, anti-CD47 antibody did not enable CDC (p > 0.2), whereas rituximab did (p < 0.001) by two-way ANOVA for both SUDHL4 and NHL17*. Combination treatment with anti-CD47 antibody and rituximab did not enable greater levels of CDC compared to rituximab (p = 0.78).
(F) CDC assay with mouse complement was performed in duplicate. Compared to IgG1 isotype control, anti-CD47 antibody did not enable CDC (p > 0.25) whereas rituximab did (p = 0.03, p = 0.08, respectively) for both SUDHL4 and NHL17*. No difference in CDC between CD47 antibody+rituximab and rituximab alone was observed (p > 0.13) for both SUDHL4 and NHL17*. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. Error bars represent SD (C-F). NHL17* = primary NHL17 cells expanded in culture. See also Figure S6 .
effectors, anti-CD47 antibody did not induce increased ADCC of Raji or SUDHL4 cells compared to IgG1 isotype control (Figure 6C) . Although rituximab did enable ADCC of these two NHL cell lines, no synergistic effect between anti-CD47 antibody and rituximab was observed (p = 0.77, Figure 6C ). As anti-CD47 antibody (B6H12.2) is a mouse IgG1 isotype, we repeated these assays with mouse NK cells. Anti-CD47 antibody caused increased ADCC of these two NHL cell lines compared to isotype control, whereas rituximab induced ADCC to a lesser degree ( Figure 6D ). To test whether anti-CD47 antibody-mediated ADCC was Fc dependent, we generated a F(ab 0 ) 2 fragment of the anti-CD47 antibody (Figures S7B-S7I ). The F(ab 0 ) 2 fragment did not enable ADCC, indicating that the increased ADCC was likely mediated through FcRs ( Figure 6D ). The combination of anti-CD47 antibody or F(ab 0 ) 2 fragment with rituximab did not induce a statistically significant increase in ADCC compared to single agent therapy, indicating no synergistic effect. Third, we investigated the role of complement in anti-CD47 antibodymediated cytotoxicity. Using either human ( Figure 6E ) or mouse ( Figure 6F ) complement, anti-CD47 antibody did not induce CDC of either an NHL cell line or a primary NHL sample, whereas rituximab did induce significant CDC against both of these samples. Moreover, the combination of anti-CD47 antibody and rituximab did not induce increased CDC compared to rituximab alone. Fourth, we investigated the relative contribution of major components of macrophages, NK cells, and complement in mediating the therapeutic effects of anti-CD47 antibody and rituximab in vivo. Luciferase-labeled Raji cells were engrafted intravenously into SCID mice, which have functional macrophages, NK cells, and complement. Mice were then separated into cohorts receiving selective depletion of either macrophages by clodronate, NK cells by anti-asialoGM1 antibody, complement by cobra venom factor, or a vehicle control. These cohorts were then treated with combination anti-CD47 antibody and rituximab therapy for 3 days, and tumor burden was measured by bioluminescent imaging pre-and post-treatment. Compared to vehicle control, NK cell and complement depletion had no effect on tumor elimination by combination antibody therapy ( Figure S6E ). In contrast, macrophage depletion significantly abrogated the therapeutic effect, indicating that macrophages, and not NK cells or complement, are required for combination anti-CD47 antibody and rituximab-mediated elimination of NHL in vivo.
Anti-CD47 Antibody Synergizes with Rituximab through FcR-Independent and FcR-Dependent Mechanisms
We hypothesize that the observed synergy between an anti-CD47 antibody and rituximab occurs through the combination of two separate mechanisms for stimulating phagocytosis: (1) FcR-independent through blockade of an inhibitory phagocytic signal by anti-CD47 antibody, and (2) FcR-dependent through delivery of a positive phagocytic signal by rituximab. We utilized four independent methods to investigate this hypothesis. First, synergistic phagocytosis was observed with the combination of anti-SIRPa antibody and rituximab by isobologram analysis ( Figure 7A ), and with a large panel of primary NHL samples (Figure 7B) . Second, mouse macrophages lacking the Fcg receptor, thereby incapable of enabling FcR-dependent phagocytosis (Takai et al., 1994) , but still expressing SIRPa ( Figure S7A ), were utilized as effector cells for phagocytosis of NHL cells incubated with either anti-CD47 antibody, anti-SIRPa antibody, rituximab, or anti-CD47/anti-SIRPa antibody in combination with rituximab. As predicted, anti-CD47 antibody and anti-SIRPa antibody, but not rituximab, enabled phagocytosis of NHL cells, without evidence of synergistic phagocytosis ( Figure 7C) .
Third, F(ab 0 ) 2 fragments of both anti-CD47 antibody and rituximab were generated (Figures S7B-S7I ) and utilized in phagocytosis assays with NHL cells and wild-type macrophages. Anti-CD47 F(ab 0 ) 2 antibody synergized with rituximab as demonstrated by isobologram analysis ( Figure 7D ). Additionally, anti-CD47 F(ab 0 ) 2 , but not rituximab F(ab 0 ) 2 , enabled phagocytosis of NHL cells ( Figure 7E ). Consistent with the proposed mechanism, synergistic phagocytosis was observed with the combination of either full-length anti-CD47 or anti-CD47 F(ab 0 ) 2 with full-length rituximab, but not with any combination involving rituximab F(ab 0 ) 2 ( Figure 7E ). Fourth, synergistic phagocytosis was investigated in vivo using GFP + Raji cells engrafted in NSG mice. As single agents, anti-CD47 antibody and rituximab enabled phagocytosis of Raji cells engrafted in the liver as evidenced by an increased percentage of mouse macrophages containing phagocytosed GFP + Raji cells ( Figure 7F ). Most significantly, combination anti-CD47 antibody and rituximab treatment enabled significantly increased phagocytosis compared to either single agent demonstrating that synergistic phagocytosis occurred in vivo ( Figure 7F ).
DISCUSSION
In this report, we identify a distinct mechanism of synergy between mAbs in cancer therapy leading to cures in the absence of chemotherapy. Specifically, we utilized a blocking anti-CD47 antibody in combination with the anti-CD20 antibody rituximab to eradicate human NHL through a mechanism of synergy involving FcR-independent enabling of phagocytosis by anti-CD47 antibody and FcR-dependent stimulation of phagocytosis by rituximab. In addition, the identification of CD47 expression as a prognostic factor could be incorporated into standard clinical prognostic considerations across multiple subtypes of NHL and may be useful in risk-adapted therapy decision-making.
Although it is thought that many therapeutic mAbs for human malignancies, including rituximab, function primarily through NK cell-mediated ADCC, several lines of evidence indicate that the therapeutic effect of anti-CD47 antibody alone or in combination with rituximab is mediated primarily through macrophage phagocytosis. First, synergistic macrophage phagocytosis was observed with combination anti-CD47 antibody and rituximab in vitro, whereas no synergy was observed for direct apoptosis, ADCC, or CDC ( Figures 2C-2E , Figure S6 , Figure 6A , and Figures  6C-6F) . Second, phagocytosis of NHL cells in vivo was observed with either anti-CD47 antibody or rituximab alone and, most importantly, significantly increased with combination therapy ( Figure 7F ). Third, the therapeutic effect of combination antibody treatment was similar in an NHL xenotransplant model using complement and NK cell-deficient NSG mice ( Figure 4C Compared to anti-CD47 antibody alone, combination anti-CD47 antibody and rituximab enabled higher levels of phagocytosis. *p < 0.05, **p < 0.01, ****p < 0.0001. Error bars represent SD (E and F). See also Figure S7 . and S4B), suggesting that macrophages alone are sufficient to mediate the therapeutic effect. Fourth, depletion of macrophages, but not complement or NK cells, abrogated the synergistic effect of anti-CD47 antibody in combination with rituximab ( Figure S6E ). These studies highlight the importance of macrophages as effectors of anti-CD47 antibody therapy in human NHL. This study describes a mechanism of antibody synergy in the elimination of NHL in the absence of chemotherapy. Combination antibody therapies for NHL have previously been investigated, mostly in combination with rituximab, with some progressing to clinical trials. These include a humanized antibody targeting the B cell antigen CD22 (epratuzumab) and galiximab, a chimeric antibody targeting the costimulatory ligand CD80. Phase I/II studies with either epratuzumab or galiximab in combination with rituximab demonstrate relative safety and clinical responses equal to or greater than single agent therapy alone (Leonard et al., 2005 (Leonard et al., , 2007 . Based on these results, phase III trials are underway. Antibody combinations involving anti-CD20 antibodies and antibodies to proapoptotic receptors are also being explored preclinically (Daniel et al., 2007; Maddipatla et al., 2007) . These studies highlight the clinical potential of combination antibody approaches in NHL patients.
Combination therapy with two or more mAbs possesses several advantages compared to monotherapies in NHL or other malignancies. First, therapy solely with monoclonal antibodies targeting cancer-specific antigens could result in decreased off-target toxicity compared to current therapeutic regimens that utilize chemotherapy. Second, synergy between two distinct antibody effector mechanisms, FcR-independent and FcRdependent as shown here, would result in increased therapeutic efficacy. Third, antibody targeting of two distinct cell-surface antigens would be more likely to eliminate cancer cells with pre-existing epitope variants or epitope loss, such as those reported in rituximab-refractory/resistant NHL patients (Foran et al., 2001; Hiraga et al., 2009; Kennedy et al., 2004) . Fourth, a bispecific FcR-engaging antibody with one arm binding and blocking CD47 and the other binding to a validated cancer antibody target (CD20) could reduce potential antibody toxicity, while retaining the synergy effect, especially as CD47 is expressed in multiple normal tissue types. Although we demonstrated that an anti-mouse CD47 antibody is relatively nontoxic to wild-type mice ), a clinical anti-human CD47 antibody may have a different human toxicity profile that could be overcome by a bispecific antibody.
In addition to its application in NHL, the reported mechanism of antibody synergy provides proof-of-principle that a blocking mAb directed against CD47 can synergize with an FcR-activating antibody to provide superior therapeutic efficacy. This finding raises the possibility of potential synergy between an anti-CD47 antibody and other clinically approved therapeutic antibodies that may activate FcRs on immune effector cells for the treatment of diverse human malignancies, including trastuzumab (Herceptin) for HER2-positive breast carcinomas, cetuximab (Erbitux) for colorectal carcinomas and head and neck squamous cell carcinomas, alemtuzumab (Campath) for CLL and T cell lymphoma, and others in development (Finn, 2008) .
To date, we have demonstrated effective anti-CD47 antibody targeting of several human cancers including AML , bladder cancer (Chan et al., 2009) , and now NHL, leading us to speculate that CD47 targeting will be effective against a wide range of human cancers.
EXPERIMENTAL PROCEDURES
Cell Lines A Burkitt's lymphoma cell line (Raji) and a DLBCL cell line (SUDHL4) were obtained from the American Type Culture Collection or generated in the lab. The NHL17* cell line was generated from a patient with DLBCL by culturing bulk cells in vitro with IMDM supplemented with 10% human AB serum for 1.5 months.
Human Samples
Normal human peripheral blood and human NHL samples were obtained from the Stanford University Medical Center (Stanford, CA, USA) with informed consent, according to an IRB-approved protocol (Stanford IRB# 13500) or with informed consent from the Norwegian Radium Hospital (Oslo, Norway) according to a Regional Ethic Committee (REK)-approved protocol (REK# 2.2007 (REK# 2. .2949 . Normal tonsils for germinal center B cell analysis were obtained from discarded tonsillectomy specimens from consented pediatric patients at Stanford University Medical Center according to an IRB-approved protocol (Stanford IRB# 13500).
Flow Cytometry Analysis
For analysis of normal peripheral blood cells, germinal center B cells, and primary NHL cells, the following antibodies were used: CD19, CD20, CD3, CD10, CD45, CD5, CD38 (Invitrogen, Carlsbad, CA, USA and BD Biosciences, San Jose, CA, USA). Analysis of CD47 expression was performed with an antihuman CD47 FITC antibody (clone B6H12.2, BD Biosciences). Cell staining and flow cytometry analysis was performed as previously described ).
Evaluation of Prognostic Value of CD47 in NHL
Gene expression and clinical data were analyzed for eight previously described cohorts of adult NHL patients, including four studies of patients with DLBCL, three with B-CLL, and one with MCL (detailed in Table S1 ). The clinical end points analyzed included overall (OS), progression free (PFS), and event-free survival (EFS), with events defined as the interval between study enrollment and need for therapy or death from any cause, with data censored for patients who did not have an event at the last follow-up visit. See Extended Experimental Procedures for a detailed description of the analyses.
Therapeutic Antibodies
Rituximab (anti-CD20, human IgG1) was obtained from the Stanford University Medical Center, mouse anti-human CD20, IgG2a from Beckman Coulter (Miami, FL, USA), and anti-CD47 antibody BRIC126, IgG2b from AbD Serotec (Raleigh, NC, USA). Other anti-CD47 antibodies were used as in Majeti et al. (2009) . All in vivo antibody experiments were performed using the anti-CD47 B6H12.2 antibody.
In Vitro Isobologram Studies
In vitro phagocytosis assays were conducted with NHL cells incubated with anti-CD47 antibody (B6H12.2), anti-CD20 IgG2a, or rituximab either alone or in combination at concentrations from 1 mg/ml to 10 mg/ml. The concentration of each antibody required to produce a defined single-agent effect (phagocytic index) was determined for each cell type. Concentrations of the two antibodies combined to achieve this same phagocytic index were then plotted on an isobologram and the combination index (CI) determined. The CI was calculated from the formula CI = (d1/D1) + (d2/D2), whereby d1 = dose of drug 1 in combination to achieve the phagocytic index, d2 = dose of drug 2 in combination to achieve the phagocytic index, D1 = dose of drug 1 alone to achieve the phagocytic index, D2 = dose of drug 2 alone to achieve the phagocytic index. A CI of less than, equal to, and greater than 1 indicates synergy, additivity, and antagonism, respectively.
Annexin V Apoptosis Assays
Assays were performed as previously described 
In Vivo Precoating Engraftment Assay
Assay were performed as previously described ). Precoated cells were transplanted intravenously into SCID mice or sublethally irradiated (200 rads) NOD.Cg-PrkdcscidIl2rgtm1Wjl/SzJ (NSG). All experiments involving mice were performed according to Stanford University institutional animal guidelines.
In Vivo Antibody Treatment in a Disseminated Lymphoma Xenograft Model 1.5 3 10 6 luciferase-labeled Raji cells were injected intravenously into the retro-orbital sinus of 6-to 10-week-old SCID or NSG mice. Those mice with luciferase-positive lymphoma were given daily intraperitoneal injections of 200 mg mouse IgG control, anti-CD47 antibody, rituximab, or 200 mg anti-CD47 antibody + 200 mg rituximab for 3 weeks. Antibody treatment was then stopped and mice were followed for survival analysis. A complete remission (CR) was defined as no evidence of lymphoma by bioluminescence at the end of treatment. A relapse was defined as evidence of lymphoma by bioluminescence after the end of treatment in a mouse with a prior CR.
In Vivo Antibody Treatment in a Localized Lymphoma Xenograft Model 3 3 10 6 luciferase-labeled Raji cells were injected subcutaneously into the right flank of 6-to 10-week-old NSG mice. Those mice with luciferase-positive lymphoma were given daily intraperitoneal injections of 400 mg mouse IgG control, 400 mg anti-CD47, 200 mg rituximab, or 400 mg anti-CD47 + 200 mg rituximab for 4 weeks. Tumor volume was measured every 3-4 days using the formula (length*width)/2. Antibody treatment was then stopped and mice were followed for survival analysis.
In Vivo Antibody Treatment of Primary NHL-Engrafted Mice 2 3 10 6 NHL cells were transplanted intravenously via retro-orbital plexus into sublethally irradiated NSG mice. Two to ten weeks later, bone marrow was aspirated from these mice and those mice with evidence of human lymphoma engraftment (hCD45 + CD19/CD10 + bone marrow cells) were then treated with the same antibody regimen as in the disseminated lymphoma model. After 14 days, bone marrow cells from these mice were aspirated and antibody treatment was stopped and mice followed for survival analysis. A CR was defined as no evidence of lymphoma in the BM at end of treatment. A relapse was defined as evidence of lymphoma in the BM after end of treatment in a mouse with a prior CR.
In Vivo Phagocytosis
In vivo phagocytosis was performed as previously described ) analyzing mice transplanted with GFP + Raji cells into adult NSG mice.
Mice were given a single dose of antibody and analyzed 4 hr later for in vivo phagocytosis.
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